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Background: The global myocardial stress response during cardiac surgery has not
been systematically studied, nor is it known whether the response of the neonatal
myocardium is intrinsically different from that of older children. To determine the
age-related molecular basis of this response, we conducted microarray-based dif-
ferential gene expression profiling on right ventricular tissue samples acquired in
patients of varying ages with right ventricular outflow tract obstruction.
Methods: We studied gene expression profiles in 24 patients during operations for
lesions involving right ventricular outflow tract obstruction age stratified into group
I (7 patients, aged 5 to 66 days; mean, 30 days) and group II (17 patients, aged 4
months to 12.5 years; mean, 2.8 years). Myocardial samples were taken from the
right ventricular outflow tract after aortic occlusion and archived in liquid nitrogen.
RNA isolation, fluorescence labeling of complementary DNA, hybridization to
spotted arrays containing 19,008 characterized or unknown human complementary
DNAs, and quantitative fluorescence scanning of gene-expression intensity were
performed at the University of Toronto Health Network Microarray Centre. Data
were analyzed with the Significance Analysis for Microarrays program. Minimum
Information About Microarray Experiments–compliant, log2-normalized data sets
were compared to ascertain potential statistical differences in gene expression
between patient groups.
Results: There were no hospital deaths or major postoperative morbid events. We
identified 50 transcripts differentially expressed in the neonatal group (the predicted
false discovery rate was 0.8 transcripts). The neonatal pattern of gene expression
(group I) was dominated by genes with literature-validated cardioprotective, antihyper-
trophic, and antiproliferative properties, including increases in atrial natriuretic peptide,
protein phosphatase 2A, small GTPase rap1, and protein inhibitor of activated STAT
protein, PIASy. Several transcripts have not been previously reported in heart.
Conclusions: Neonatal myocardium has a unique pattern of gene expression, which
may result from developmental (age-related) differences or reflect a more severe
disease phenotype independent of age effects per se. The neonatal transcript profile
seems to reflect a stress-induced protective program composed of genes with
functions diametrically opposed to those expected to be related to the pathogenesis
of critical right ventricular outflow tract obstruction, thus revealing a novel and
compensatory antidisease transcriptional response in the neonatal heart.
Considerable evidence supports the idea that the newborn mamma-lian heart has intrinsically greater resiliency in response to meta-bolic and hemodynamic stress than the mature heart, presumablybecause of a greater repertoire of inducible and cytoprotective geneprograms. For example, neonatal rabbit hearts adapted to hypoxiaexhibit improved functional recovery in response to a subsequently
imposed ischemic stress.1 This cardioprotective effect has been attributed to in-
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creased activity of endothelial nitric oxide synthase produc-
tion of nitric oxide in association with increased cyclic
guanosine monophosphate (cGMP) levels.2 There is also
precedence for developmental regulation of hypoxia-induc-
ible factor, a transcription factor that binds under hypoxic
conditions to an enhancer element in the 3' region of the
erythropoietin gene and for which there are decreasing
message levels from fetus to neonate to adult.3 Additional
evidence for adaptive hypoxia-induced responses in the
neonatal heart include the observed increase in apoptotic
threshold in intact rat heart through downmodulation of
myocardial ceramide levels,4 the energetically favorable
reduction in global RNA and protein synthesis in isolated
cardiomyocytes,5 and the antiapoptotic effects associated
with ectopic expression of cdk inhibitors p21CIP and
p27KIP1.6
The evidence for the developmentally regulated capacity
of the immature heart to generate an adaptive response to
reduced oxygen availability, although compelling, is de-
rived largely from acute experimental interventions in ani-
mal models. Further, the reductionist approach of these
studies, which typically address a single target, fails to
capture the global complexity of the response. Nevertheless,
the general observation that the human neonatal heart copes
well with dramatic degrees of hypoxia and hypertrophy is in
accordance with these experimental findings. To determine
the molecular basis of this putatively adaptive response, we
conducted microarray-based differential gene expression
profiling on tissue samples acquired in patients of varying
ages undergoing repair of right ventricular (RV) obstructive
heart lesions, focusing on potential age-related differences.
Methods
Patients
Consent to conduct tissue sample analysis was obtained from the
Research Ethics Board of the Hospital for Sick Children, Toronto.
Myocardial samples were taken in 24 patients, ranging in age from
6 days to 12.5 years, who were operated on for obstructive heart
lesions. The samples were taken from muscular trabeculae of the
endocardial surface of the RV infundibulum, were acquired im-
mediately after aortic occlusion and standard blood cardioplegia
administration, and were stored in liquid nitrogen. The patients
were divided into 2 groups. Group I consisted of 7 patients (2
females and 5 males). Age ranged from 5 to 66 days (mean, 30
days); weight ranged from 2.5 to 4.9 kg (mean, 3.6 kg). The
diagnoses included tetralogy of Fallot (TF; n  4), complex
transposition (n  2), and truncus arteriosus (n  1). Group II
consisted of 17 patients (6 females and 11 males). Age ranged
from 4 months to 12.5 years (mean, 2.8 years); weight ranged from
5.18 to 33.5 kg (mean, 11.3 kg). The diagnoses in group II
included TF with (n  1) or without (n  16) pulmonary atresia.
One patient underwent RV to pulmonary conduit change subse-
quent to repair of ventricular septal defect and subaortic stenosis
by a Damus-Kaye-Stansel procedure.
Gene-Expression Analysis
RNA isolation. Total RNA was isolated from tissue samples
by using Trizol reagent according to the protocol outlined by the
manufacturer (Gibco/BRL). Briefly, frozen tissues were powdered
with a mortar and pestle, cooled in liquid nitrogen, and then further
manually homogenized in a microtube by using disposable homog-
enizers in the presence of the Trizol reagent. RNA concentrations
were determined spectrophotometrically at 260 nm, and quality
was confirmed by running a 50- to 250-ng aliquot on the Agilent
2100 Bioanalyzer (Palo Alto, Calif). All samples were stored at
70°C until analyzed. Universal Human Reference RNA (Strat-
agene, La Jolla, Calif) was used as the reference sample for all
hybridizations.
Arraying procedure and processing. Microarrays were man-
ufactured at the University of Toronto Microarray Centre (To-
ronto, Canada) by using complementary DNAs (cDNAs) gener-
ated from 19,000 individual cDNAs from Genome Systems (St
Louis, Mo). The cDNA inserts were polymerase chain reaction
(PCR)-amplified from the pT7T3D-Pac vectors in 96-well format.
The name and identification of each of the expressed sequence tags
(ESTs) used in the production of the slide can be found at
http://www.microarrays.ca/.
Hybridization. Resuspended samples of fluorescence-labeled
cDNA were added to a hybridization mixture containing 80 L of
DIG Easyhyb (Roche, Mississauga, Canada), 4 L of yeast trans-
fer RNA (10 g/L), and 4 L of salmon sperm DNA (10 g/L;
Sigma, Mississauga, Canada). Samples were heated to 65°C for 2
minutes, cooled briefly, and centrifuged to bring down any con-
densate that may have accumulated during heating. The entire
volume was applied to the microarray, placed in a sealed, humid-
ified hybridization chamber, and incubated overnight at 37°C.
Slides were then washed consecutively in 1 standard saline
citrate and 0.1% sodium dodecyl sulfate for 30 minutes at 50°C. A
final rinse was performed at room temperature in 0.1 standard
saline citrate for 5 minutes, and the slides were then centrifuged for
5 minutes at 500 rpm to dry.
Scanning and quantification. Slides were scanned on a scan-
ning laser fluorescence confocal microscope (ScanArray 4000XL;
PerkinElmer, Boston, Mass). Individual 16-bit Tagged Image File
Format (TIFF) images were obtained by scanning for each of the
2 fluors. An overlay image of the 2 images was created and
quantified with the QuantArray (version 2.1) program (Perkin-
Elmer). Intensity values for each spot were normalized, and ratios
were calculated, resulting in value of patient sample normalized to
Universal Human Reference RNA. Individual spots had to pass a
number of quality criteria to be included in the data analysis,
including a minimum spot/local background intensity greater than
or equal to 1, a minimum spot/mean background intensity greater
than or equal to 1, and a minimum spot intensity of 100.
Data analysis. Data were stored in and analyzed with the
GeneTraffic Microarray Database and Analysis System (Iobion
Informatics, La Jolla, Calif), as well as the Significance Analysis
for Microarrays program.7 Scanned 16-bit TIFF images represent-
ing each hybridized microarray slide and the associated quantifi-
cation data files were entered into the database with a complete
annotation of the experiments based on the current Minimum
Information About Microarray Experiments standards for microar-
ray experiments (http://www.mged.org).
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Each hybridization data set was normalized with Lowess sub-
array normalization (http://oz.berkeley.edu/tech-reports/). Lowess
normalization uses a local weighted smoother to generate an
intensity-dependent normalization function. In subarray normal-
ization, each subarray or grid is normalized individually to correct
for variation in local mean signal intensities across the surface of
the array.8 The resultant normalized log2 patient/sample intensity
ratios were used for statistical analysis. A repeated permutation
procedure was performed to ascertain potential statistical differ-
ences in gene expression between the 2 age groups.7 The median
false discovery rate, based on analysis of permuted data sets, was
less than 1.0%, and only genes with a minimum 2-fold change in
expression were selected. Results from the Significance Analysis
for Microarrays analysis were visualized as hierarchical clusters in
TreeView (Eisen Lab, Berkeley, Calif).
Validation with real-time PCR. Independent confirmation of
increased transcription levels was performed by using real-time
quantitative PCR (qPCR) on 4 randomly selected genes that
showed increased neonatal expression. Primers were constructed
against the 3' ends of fibroblastic growth factor (FGF)-1 (acidic),
hepatoma-derived growth factor (HDGF), syntenin, and early
growth response (egr-1), and amplicon abundance was determined
in real time by SYBR Green Dye (Applied Biosystems, Foster
City, Calif) fluorescence measurement during the logarithmic
phase and normalized to that of a control gene, cyclophilin. Fold
changes for the cyclophilin-normalized value of each transcript
were determined as a ratio of sample patient RNA to that of the
Universal Human Reference RNA. Multiple regression analysis
was performed to compare intergroup differences in transcript fold
changes determined by microarray analysis versus qPCR for each
of the selected genes.
Two-step reverse transcriptase–PCR was performed as outlined
in the SYBER Green PCR Master Mix protocol (Applied Biosys-
tems). To synthesize cDNA, 2 g of deoxyribonuclease-treated
RNA was added to a reaction mixture containing the following: 8
L of 5 first-strand buffer (Life Technologies), 1.5 L of AncT
primer (T20VN), 5 mol/L of a 500 mol/L deoxynucleoside
triphosphate mix (deoxyadenosine triphosphate, deoxycytidine
triphosphate, and deoxyguanosine triphosphate), and 10 mmol/L
dithiothreitol. Final reaction volumes were brought up to 40 L,
and primer annealing was initiated by heating the reaction mix to
65°C for 5 minutes and then 42°C for 5 minutes. Reactions were
initiated by the addition of 2 L of Superscript II reverse tran-
scriptase (Life Technologies; 200 U/L) and allowed to proceed
for 2 hours at 42°C. Primers were designed by using PrimerEx-
press 2.0 (Applied Biosystems) directed toward the 3' sequence of
each clone. Primer sequences were as follows: atrial natriuretic
factor (5'-GCTCCTAGGTCAGACCAGAGCTAA; 3'-TTCTTC-
CAAATGGTCCAGCAA), egr-1 (5'-CCTTCGCTAACCCCTC-
TGTCTA; 3'-TGGGACTGGTAGCTGGTATTGAG), syndecan
(5'-AATACATGGCTTGCTGCCTGTT; 3'-GGATGGTACGCTTG-
GTCTTGA), and hepatoma growth factor (5'-CAGTGTCATTTCT-
CATCCACATACC; 3'-TCTCTCTGTCCTCTCAGTGGGTTAC).
Samples were diluted 100-fold and added to the reaction mix
containing SYBER Green PCR Master Mix and the appropriate
primers to a final volume of 25 L. All samples were run in
triplicate on the ABI Prism 7900 detection system (Applied Bio-
systems). All samples were analyzed relative to human cyclophi-
lin. Calculation of relative quantities of the various products was
determined with the relative standard curve method using the ABI
Prism 7900 sequenced detection system spectral calibration kit
(Applied Biosystems).
Results
All patients survived the surgical procedure and were dis-
charged from the hospital. One neonate with a Taussig-Bing
anomaly plus an atrioventricular septal defect required post-
operative extracorporeal membrane oxygenation. There
were no significant differences in preoperative arterial sat-
uration between the 2 age groups (group I, 79.85% 
12.5%; group II, 87.24% 12.9%; P .21). There were no
differences in preoperative central venous pressure (group I,
7.2  2.3 mm Hg; group II, 7.4  2.6 mm Hg; P  .85) or
postoperative inotropic support (dopamine: group I, mean,
4.5  2.74 g kg/min; group II, 4.5  3.01 g kg/min;
milrinone: group I, 0.53  0.29 g kg/min; group II, 0.26
 0.31 g kg/min; P  .11).
We found that 38 genes (the term gene is used denote a
unique UniGene cluster ID in this discussion) exhibited
significantly different expression levels between groups I
and II (Figure 1 and Table 1). Thirty-four genes showed
increased expression levels in group I, whereas 4 gene
elements exhibited repressed transcription in group I in
comparison to group II.
Significant genes were searched by using The Stanford
Online Universal Resource for Clones and ESTs
(SOURCE), which compiles information from several pub-
licly accessible databases, including UniGene, dbEST,
Swiss-Prot, GeneMap99, RHdb, GeneCards, and LocusLink
(http://genome-www5.stanford.edu/cgi-bin/SMD/source/
sourceSearch). Several genes are literature validated as hav-
ing a protective effect against experimentally induced myo-
cardial ischemia/reperfusion injury, including atrial
natriuretic polypeptide (ANP), HDGF, syndecan-binding
protein (syntenin), toll-interleukin-1 receptor, and insulin-
like growth factor-2 (somatomedin A; indicated with an
asterisk in Table 1). Several additional genes have docu-
mented antigrowth properties and may be speculated to
resist cardiac hypertrophy and promote vasodilation, includ-
ing the small guanosine triphosphatase rap1, the transcrip-
tional repressor zinc finger protein-7, protein phosphatase-2,
ubiquitin-specific protease-15, and egr-1. The finding of
decreased transcript expression of FGF-1 (acidic; indicated
with a dagger in Table 1) would be predicted to confer
additional net antiproliferative effects. Several genes have
been previously designated as “fetal” genes, including ANP,
HDGF, and keratin, hair, basic, 5. The remaining genes are
unprecedented in terms of predicted cardiovascular effects
(black typeface in Table 1). Intergroup differences in 4
randomly selected transcripts levels determined by microar-
ray analysis were highly correlated with those determined
by qPCR (multiple R2  0.998; P  .001).
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Figure 1. Hierarchical clustering of gene-expression data of the 24 patients operated on for RV outflow tract
obstruction. Each row represents a separate cDNA clone on the microarray, and each column represents a
messenger RNA (mRNA) sample from a separate patient. Patient mRNA samples are separated in 2 groups as
indicated on the top. The results represent the ratio of hybridization of fluorescent cDNA probes prepared from
each patient mRNA sample to a reference mRNA sample and are a measure of gene-specific expression levels.
Red indicates higher expression and green indicates lower expression relative to the reference sample.
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Discussion
Among the estimated 32,000 to 38,000 genes encoded by
the human genome, approximately 20,000 to 25,000 are
thought to be expressed in the cardiovascular system.9 The
combinatorial pattern of gene expression in the heart serves
to increase the repertoire of responses to pathologic stress,
and it is intuitively logical that the capacity for such adap-
tive responses is inversely related to the fetal-neonatal-adult
development gradient. The results of this microarray-based
gene expression profiling study seem to confirm the exis-
tence of a protective reprogramming response that is most
evident in the neonatal myocardium and is subject to the
hemodynamic and metabolic stress imposed by structural
congenital heart disease.
Disease-specific expression profiles have also implicated
unexpected or novel molecular targets in the pathogenesis
of human cardiovascular disease, including cardiac hyper-
trophy,10 dilated cardiomyopathy,11 and the clinical re-
sponse to -blockade in patients with dilated cardiomyop-
athy12 (see review13). The molecular signatures identified
with this approach are typically construed as either mecha-
nistically relevant to the disease pathogenesis or, alterna-
tively, as markers of disease progression. In contrast, we
believe that this approach can be used to identify endoge-
nous patterns of gene expression that are activated in re-
sponse to the primary disease-causing pathway and have the
effect of generating a counteracting and highly adaptive
pattern of gene activation, which serves to suppress aberrant
disease-related molecular pathways. The transcriptional
profile in the neonatal group was characterized by increased
expression levels of genes with literature-validated antihy-
pertrophic and cytoprotective properties.
Atrial Natriuretic Polypeptide
The effects of ANP are mediated through binding to the
A-type natriuretic peptide receptor that activates guanyl
cyclase, leading to the formation of cGMP.14,15 Upregula-
tion of ANP expression in occurs in all 4 cardiac chambers
in response to acute and chronic hypoxic stress,16-18 imply-
ing that the ANP may represent a hypoxia-inducible gene
per se, the regulation of which can occur independently of
changes in pulmonary artery pressure and ventricular hy-
pertrophy. The fact that there were no significant differences
in saturation levels between the 2 age groups argues that the
increased ANP response observed neonatally reflects an
age-dependent enhancement to hypoxic signaling rather
than a response commensurate with a greater degree of
hypoxia. Similarly, the lack of intergroup differences in
central venous pressure rules out stretch-induced ANP ac-
tivation as an explanation for differential expression.
The direct effect of ANP on myocardial ischemia/reper-
fusion injury is unknown; however, the fact that ANP in-
creases cGMP levels, inhibits proapoptotic p38 mitogen-
TABLE 1
Confirmed
clone ID
Confirmed
UniGene
cluster ID Gene name
Up-regulated*
301819 Hs.75640 Natriuretic peptide precursor A*
245371 Hs.356717 Myosin, light polypeptide 4*
5749628 Hs.356717 Myosin, light polypeptide 4, alkali; atrial,
embryonic
4754192 Hs.111779 Secreted protein, acidic, cysteine-rich
(osteonectin)
5405119 Hs.119571 Collagen, type III, alpha 1
363968 Hs.111779 Secreted protein, acidic, cysteine-rich
(osteonectin)
110787 Hs.226103 Homo sapiens mRNA; cDNA
DKFZp564G222
5704539 Hs.75617 Collagen, type IV, alpha 2
301788 Hs.75636 Myosin light chain 2a*
144223 Hs.152931 Lamin B receptor
134272 Hs.89525 Hepatoma-derived growth factor*
6050536 Hs.334842 Tubulin, alpha, ubiquitous
120176 Hs.7940 RAP1, GTP-GDP dissociation stimulator 1†
N/A Hs.433622 Follistatin-like 1
341679 Hs.182507 Keratin, hair, basic, 5
258999 Hs.119571 Collagen, type III, alpha 1
429072 Hs.2076 Zinc finger protein 7 (KOX 4, clone
HF.16)
5740157 Hs.74405 Tyrosine 3-monooxygenase/tryptophan
5-monooxygenase activation protein,
theta polypeptide
120375 Hs.17681 Toll-interleukin 1 receptor (TIR)*
110331 Hs.108885 Collagen, type VI, alpha 1
502114 Hs.23168 Ubiquitin specific protease 15†
N/A Hs.75248 Topoisomerase (DNA) II beta 180kDa
182411 Hs.326035 Early growth response 1†
115434 Hs.10739 ESTs
327591 Hs.356350 Hypothetical protein LOC283970
182871 Hs.15725 Immediate early response 5†
111571 Hs.142442 HP1-BP74
184151 Hs.159154 Tubulin, beta, 4
148703 Hs.105779 Protein inhibitor of activated STAT
protein PIASy†
4730276 Hs.349109 Insulin-like growth factor 2
(somatomedin A)*
299022 Hs.300711 Annexin A5
154604 Hs.107125 Plasmalemma vesicle associated protein
2463766 Hs.116992 ESTs, moderately similar to A chain A,
human homogentisate dioxygenase
271985 Hs.2053 Tyrosinase (oculocutaneous albinism IA)
469697 Hs.80350 Protein phosphatase 2 (formerly 2A)†
N/A Hs.75975 Signal recognition particle 9kDa
Down-regulated*
5750213 Hs.177776 Hypothetical protein MGC4276 similar to
CG8198
270544 Hs.270956 Chromosome 4 open reading frame 1
282695 Hs.75297 Fibroblast growth factor 1 (acidic)*
138757 Hs.28427 ESTs
*Literature-validated cardioprotective properties.
†Unprecedented cardiovascular properties.
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activated protein kinase activation, and antagonizes tumor
necrosis factor-–induced changes in the endothelial cell
cytoskeleton and prevents macromolecule permeability
changes19 is highly suggestive of a novel cytoprotective
effect in this context. Recombinant ANP peptide has been
shown to potentiate myocardial ischemic preconditioning
through a nitric oxide–dependent mechanism.20 Additional
cytoprotective effects may accrue from upregulation of the
toll-interleukin-1 receptor21 and insulin-like grown factor-
2,22 attributable to activation of ischemic preconditioning
and antiapoptotic signaling pathways, respectively.
It is unknown whether ANP gene induction in the heart
confers a direct cytoprotective effect against excessive, or
pathologic, hypertrophic or hypoxic stimuli independently
of its vasoreactive and natriuretic properties. Consistent
with this prediction, however, are the observations that
exogenous or endogenous ANP peptide suppressively reg-
ulates the cardiac hypertrophic response in an autocrine/
paracrine manner by increasing myocyte cGMP levels in
neonatal rat cardiomyocytes in vitro23 and that transgenic
mice overexpressing ANP have lower heart weights under
normoxic conditions and an attenuated RV hypertrophic
response to hypoxia-induced pulmonary hypertension.24
A decline in ventricular ANP gene transcription nor-
mally occurs postnatally concurrently with a switch from a
right to left ventricular dominant circulation25-27; this pro-
vides an explanation for neonatal expression of this tran-
script in the presence of RV outflow tract obstruction.
However, the fact that expression levels of 2 other hyper-
trophy-associated genes, -myosin heavy chain and endo-
thelin-1, were not found to be differentially expressed in our
study, argues that neonatal upregulation of ANP is func-
tionally important and not simply a marker of hypertrophic
stress. We speculate that ANP gene activation in the context
of neonatal obstructive heart disease may serve to mitigate
excessive hypertrophic signaling and protect against the
transition from physiological to pathologic hypertrophy.
Protein Phosphatase-2A
Transgenic mice overexpressing protein phosphatase-2A
exhibit reduced cardiac contractility and progressive ven-
tricular dilation, an effect that may serve to mitigate the
concentric hypertrophic response inherent in neonatal TF28
and that may be attributable to protein phosphatase-2A–
mediated antagonism to calcium calmodulin–dependent
protein kinase activity.29 In vascular smooth muscle cells,
protein phosphatase-2A inhibits platelet-derived growth
factor-BB–mediated phosphorylation of BAD and forkhead
transcription factor FKHR-L1, and this effect correlates
with increased apoptosis.30 Further, protein phosphatase-2A
is predicted from sequence similarity to cause deactivating
dephosphorylation of the carboxy terminal domain of RNA
polymerase II and would be predicted to be limiting to
cardiac hypertrophic growth.31 Thus, antihypertrophic sig-
naling described for this phosphatase may thus be predicted
to complement favorable cardiac vascular remodeling at-
tributable to increased ANP.
Early Growth Response-1
egr-1 is a zinc finger transcription factor that exerts oppos-
ing effects depending on the latency of the measured re-
sponse and the contextual pattern of co-regulated gene
expression. For example, growth factors and cytokines in-
cluding platelet-derived growth factor, angiotensin II, tumor
necrosis factor- and -, and interleukin-1 increase the
egr-1 message within 15 minutes,32 which, in turn, activates
transcription of several genes implicated in the pathogenesis
of vascular diseases, including tumor necrosis factor-,33
platelet-derived growth factor (PGDF),34 interleukin-2,32
and FGF,35 producing a positive amplification loop that
favors smooth muscle cell proliferation.
Conversely, egr-1 exerts a counterregulatory effect
through a sustainable transactivation of peroxisome prolif-
erator-activated receptor-1, itself a ligand-activated nu-
clear transcription factor that potently suppresses growth
factor– and cytokine-mediated signaling in vascular smooth
muscle,32,36 possibly accounting for the reduced FGF mes-
sage observed in the neonatal group. Thus, in addition to
mitigation of hypertrophic cardiomyocyte signaling, coor-
dinated expression of ANP, egr-1, and protein phospha-
tase-2A would be predicted to favor vascular smooth mus-
cle regression promoting coronary vasodilation and having
the effect of augmenting oxygen delivery to hypertrophic,
hypoxically perfused myocardium. Although they are not
literature-validated as cardiac targets, increased neonatal
expression of the small guanosine triphosphatase rap1,
which inhibits the extracellular signal-related kinase signal-
ing cascade,37 and the transcriptional repressor zinc finger
protein-738 could plausibly further limit hypertrophic re-
sponses in the hemodynamically stressed heart.
Several genes differentially expressed in the neonatal
group conceivably augment the capacity for matrix remod-
eling and cellular regeneration, including the re-expression
or, more likely, persistence of “fetal” genes, implying par-
allels between physiological fetal and stress-induced tissue
remodeling. The gene specifying secreted protein, acidic,
rich in cysteine (osteonectin) is a developmentally regulated
matricellular protein involved in wound healing and tissue
repair39 and may promote favorable extracellular matrix
remodeling.40 Hepatoma-derived growth factor is a nuclear-
targeted growth factor conspicuously expressed in embry-
onic ventricular myocytes, endocardium, and cells of the
ventricular outflow tract, implying a role in cardiovascular
growth and differentiation.41 Although not specified as a
fetal gene, egr-1 may promote adaptive matrix remodeling
by virtue of its capacity to stimulate angiogenesis,42 endo-
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thelial production of membrane type 1 matrix metallopro-
teinase,43 and accrual of fibrin stroma through upregulation
of plasminogen activator inhibitor-1.44,45 egr-1–mediated
upregulation of plasminogen activator inhibitor-1 (also
known as serpine-1)44 may serve an important adaptive
function by increasing the fibrin stroma on which neoan-
giogenesis and tissue repair may take place.45
An unexpected finding of global gene analysis of heart
tissue in this study was the evidence for antigrowth prop-
erties of several transcripts, including the tumor-suppressor
genes egr-1, ubiquitin-specific protease-15, and the tran-
scriptional repressor zinc finger protein 7, in concert with
reduced levels of FGF-1 messenger RNA. This antigrowth
program is thematically consistent with a greater compen-
satory reaction to hyperproliferative signals in the immature
heart, which may serve to protect against the development
of pathologic interstitial fibrosis.
Limitations of the Study
Need for independent validation of microarray data.
Technical and biological sources of variation are inherent in
microarray experiments. Our study design incorporated bi-
ological replication (based on analysis of multiple patients)
rather than performing multiple technical (array) replicates.
This design has been recommended to maximize degrees of
freedom and statistical precision in studies of this nature.46
Further, the correlation between duplicate spots used in our
arrays exceeded 96% among the significant genes, although
this does not necessarily guarantee interhybridization repro-
ducibility across different arrays.46 The statistically high
correlation of transcript levels determined with microarray
and qPCR methods provides strong support for the validity
of our findings.
We used the false discovery rate, which determines the
percentage of positive calls that are false positives. This
parameter is computed by permutation analysis, which com-
pares the observed differences in gene-specific intensity
values between the 2 age groups with that expected from
random assignment of values between the 2 age groups. The
false discovery rate is a tunable parameter and was set to
less than 1%. This approach is considered preferable to P
value calculations, which, in microarray data analysis, ne-
cessitate the use of multiple comparison adjustment
algorithms.7
Lack of homogeneous patient diagnosis. Although all
patients in the neonatal group had RV outflow tract obstruc-
tion, 2 had complex transposition and 1 had truncus arteri-
osus. The neonatal group thus differed in both age and
diagnosis from the older cohort group, and the neonatal
patients may represent a more severe disease phenotype.
Regardless of whether the transcriptional response in the
neonate results from immaturity or, alternatively, disease-
specific factors, the biological properties of the neonatal
expression pattern are plausibly suppressive to cardiac hy-
pertrophy. The fact that the differentially expressed gene
elements thematically clustered into genes predicted to have
cardioprotective properties, often consistent with a less dif-
ferentiated (fetal) state, itself lends further validity to the
biological significance of our findings. It is also noteworthy
that unsupervised clustering analysis (ie, without a priori
age stratification) correctly classified 6 of the 7 youngest
patients (data not shown).
The constituent cell types in the heart that are responsible
for the observed gene expression patterns are not discernible
from this study, nor is it known whether the tissue compo-
sition of cardiomyocytes, fibroblasts, endothelial cells, and
trafficking cells is the same in both patient groups. Finally,
the interpretation of these microarray data is speculative and
requires orthogonal validation through experimentation or
in silico comparative analysis by using age- and diagnosis-
specific, standards-compliant data sets.
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Discussion
Dr Peter J. Gruber (Philadelphia, Pa). I compliment Dr
Konstantinov, Dr Coles, and their Toronto colleagues on their
near-comprehensive analysis of age-related gene expression pat-
terns in children with right heart obstructive lesions. The incorpo-
ration of contemporary molecular techniques, those that are now
standardized in other scientific disciplines, to cardiac surgery pro-
vides powerful tools to advance understanding of congenital heart
disease and especially its interaction with surgery at a basic level.
Genomic, naive approaches such as those just described in com-
parison to candidate-based techniques allow one to identify un-
foreseen molecules and thus provide the opportunity for new
testable hypotheses.
It is in this hypothesis generation, rather than discrete findings,
that expression profiling is generally most valuable. I have 3 brief
questions. One limitation of the study is the use of single arrays
rather than replicates. Nonrandomization of spotting on arrays in
addition to interchip variability can have profound effects on
expression levels. Although qPCR confirmation of selected targets
was performed, I’m interested to know whether this was consid-
ered in other ways.
Second, I reluctantly bring up the issue of correlation, or rather
the lack of correlation, between messenger RNA (mRNA) levels,
protein levels, and function. Considerable work has been done in
yeast and other organisms demonstrating that mRNA levels are in
fact insufficient to predict protein expression levels in any way.
Additionally, protein levels, although 1 step closer to physiology,
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only partially correlate with function because conservatively, there
are at least 20 modifications such as phosphorylation, lipidation,
glycosylation, or sumoylation per protein. So I would be interested
to know how you interpret your work in light of the lack of
predictive value of mRNA with respect to function in any indi-
vidual gene.
Last, given the hypotheses generated with respect to the current
study, I would like to know what you think are your most prom-
ising leads, and of those, which ones would you follow up in which
direction?
Dr Coles. Thank you, Dr Gruber, for your insightful questions.
Regarding the use of single arrays, we relied on biological repli-
cate variability by including as many patients as we could, and
using that approach effectively eclipses the need for multiple
technical arrays.
We also spotted each cDNA array in duplicate or quadruplicate,
and we found a very high concordance among the expression
levels in each of the duplicate spots, and that, coupled with the
PCR results, gave us confidence that we were getting bona fide
results.
Your question is very germane regarding protein analysis. As
you point out, posttranslational modifications may affect the ulti-
mate phenotype in a way that’s not necessarily predicted by the
mRNA. We think, however, that the transcriptional response by
itself can be informative and clearly was different between the
newborn heart and the older cohort patients. Regardless of which
particular approach is used, I certainly agree with the need for
independent validation and clinical corroboration of any of the
putative targets that we found.
In response to your final question as to follow-up, it is a very
challenging problem to do target triage to pick the leads that you
think are going to be best, recognizing that in many cases, it is
really the combinatorial pattern of genes that affects the ultimate
phenotype. So it is hard to pick one out in isolation.
But I did mention that ANP has already been identified, and
actually brain natriuretic peptide, its analog, turns out to be a
blockbuster drug for left ventricular heart failure. So this does
suggest, at least by circumstantial evidence, that some of these
targets will have a potential clinical impact.
We are intrigued personally with the phosphatase theme. Fol-
lowing up that in terms of drug discovery and downstream anal-
ysis, it is a very difficult, specialized project. Delivery of phos-
phatases, since they are large proteins, becomes an issue. The best
approach is to try and find drugs that are receptors that can be
given systemically.
We don’t yet have any results with that approach, but that’s
really phase II target validation, which we look forward to
doing.
Dr Richard A. Jonas (Boston, Mass). John, did you have
enough spread of oxygen levels to get a sense as to whether the
gene expression changes that you were seeing were in response to
pressure load hypertrophy versus cyanosis?
Dr Coles. No. The saturation levels were a little bit lower in the
neonatal group, suggesting that there may be a bias there, but the
differences weren’t statistically significant.
The other thing is, is it really a complex stress, as you imply it
is? There is hypertrophy, there is hypoxia, and there are any
number of metabolic factors acting on these patients, and so is it
really an oversimplification to say that the differences are due to
age per se?
Dr Bradley Allen (Houston, Tex). That was sort of my ques-
tion. Can you really say it is age versus stress since the stresses are
so much different in the neonate compared to the older cohort? I
would think the only way to prove this would be if the neonates
that underwent a greater degree of stress, such as hemodynamic
instability, lower O2 saturation, etc, had more gene expression.
Otherwise, you can’t say how much of the change might be due to
differences in stresses versus age.
Dr Coles. I would certainly agree with that. In fact, I would
likely hazard to guess that the newborn hearts were in fact at the
more severe spectrum of disease, and that’s why they presented in
the neonatal period, and therefore they had a higher stress.
Nevertheless, our interpretation was that greater disease sever-
ity would elicit a commensurately greater antistress response, and
this was reflected, if you will, in the higher dose of protective
genes that we found.
The higher stress or the young age, whatever the explanation,
is, in a sense, irrelevant. What we are looking for is a way to
exploit the differences that would identify cytoprotective proper-
ties.
Dr Jonas. John, these arrays are quite expensive. Roughly what
sort of cost are you looking at for this type of array?
Dr Coles. Well, this was sort of a homegrown academic thing,
and it was free for us through our academic collaborators.
We used spotted glass arrays slides. Most people seem to be
converging on the Affymetrix platform, and they are about
US$600 per array.
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